Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the business's stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $39,760.20. Following the completion of the sale, the chief financial officer directly owned 51,647 shares of the company's stock, valued at $859,922.55. The trade was a 4.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Houte Hans Van also recently made the following trade(s):
- On Friday, January 30th, Houte Hans Van sold 3,661 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60.
Nurix Therapeutics Stock Up 0.5%
NRIX opened at $16.70 on Friday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -5.28 and a beta of 1.97. Nurix Therapeutics, Inc. has a fifty-two week low of $8.19 and a fifty-two week high of $22.50. The company's 50-day moving average price is $15.83 and its 200 day moving average price is $15.99.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The firm had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.92 earnings per share for the current year.
Analyst Ratings Changes
NRIX has been the subject of several recent analyst reports. Morgan Stanley set a $36.00 target price on shares of Nurix Therapeutics and gave the stock an "overweight" rating in a research report on Thursday, January 8th. HC Wainwright restated a "buy" rating and issued a $32.00 target price on shares of Nurix Therapeutics in a research report on Monday. Royal Bank Of Canada increased their price objective on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the company an "outperform" rating in a report on Thursday, January 29th. Stifel Nicolaus increased their price objective on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nurix Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.46.
Get Our Latest Stock Analysis on Nurix Therapeutics
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd acquired a new position in Nurix Therapeutics in the first quarter worth approximately $855,000. Flax Pond Capital LLC acquired a new position in Nurix Therapeutics in the fourth quarter worth approximately $1,521,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics in the fourth quarter worth approximately $53,000. Seven Fleet Capital Management LP acquired a new position in Nurix Therapeutics in the fourth quarter worth approximately $379,000. Finally, Invesco Ltd. grew its position in Nurix Therapeutics by 115.0% in the fourth quarter. Invesco Ltd. now owns 343,830 shares of the company's stock worth $6,522,000 after buying an additional 183,909 shares during the last quarter.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company's pipeline includes multiple programs in various stages of development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
